| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bicalutamide | FIMM | pan-cancer | AAC | -0.35 | 0.06 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.063 | 0.06 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.06 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.054 | 0.06 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.073 | 0.06 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.06 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.068 | 0.06 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.098 | 0.06 |
| mRNA | pifithrin-alpha | CTRPv2 | pan-cancer | AAC | 0.071 | 0.06 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.059 | 0.06 |